Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00460382 |
|
Recruitment Status
:
Completed
First Posted
: April 13, 2007
Last Update Posted
: September 17, 2010
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections | Drug: raltegravir potassium Drug: darunavir/ritonavir Drug: etravirine Drug: Optimized background regimen | Phase 2 |
Methods: A phase II pilot, prospective, open label, single arm multicentric clinical trial assessing a darunavir/ritonavir, etravirine and MK-0518-containing regimen, if possible associated to an optimized background regimen that may include NRTIs and enfuvirtide, in HIV-1 infected patients failing combination antiretroviral therapy with multi-resistant viruses.
Treatment strategy: Patients will receive raltegravir (MK-0518), darunavir/ritonavir (TMC114/r) and etravirine (TMC125) and if possible an optimized background therapy.
- raltegravir (MK-0518) (400 mg x 2/d = one 400 mg pill twice daily)
- darunavir (600 mg x 2/d= two 300 mg pills twice daily with meal)
- ritonavir (100 mg x 2/d = one 100 mg pill twice daily with meal)
- etravirine (200 mg x 2/d = two 100 mg pills twice daily with meal)
- if possible an optimized background therapy: may include NRTI(s) and enfuvirtide but not nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). NRTIs choice is left to the clinician's discretion. Enfuvirtide is highly recommended in enfuvirtide-naive patients but is left to the clinician.
Main outcome: proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at W24.
Secondary outcomes: proportions of patients with HIV RNA levels of less than 50 copies/ml at week 48, with HIV RNA levels of less than 400 copies/ml at week 24 and 48; HIV RNA level evolution between baseline and week 48; HIV proviral DNA and 2LTR circle HIV DNA between baseline and week 48; number and type of resistance mutations in case of virologic failure occurrence; CD4 lymphocyte count and proportion evolution between baseline and week 48; HIV infection progression; frequency of the study regimen modifications and interruption; study regimen tolerance; study regimen adherence; association between study drugs' minimum concentrations at week 4 and virologic success at week 24; evolution of pharmacokinetic parameters of study drugs between week 1 and week 4 in the Pharmacokinetic substudy.
Sample size: 103 patients
Enrollment period: 24 weeks
Patient's participation duration: 52 weeks
An extended follow-up (from week 52 to week 96) has been added in April 2008.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 103 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Prospective Clinical Trial to Assess Safety and Efficacy of DRV/r(TMC 114/r), ETV(TMC 125) and MK-0518 in Addition to OBT in HIV-1 Infected Patients With Limited to No Treatment Options ANRS 139 TRIO |
| Study Start Date : | May 2007 |
| Actual Primary Completion Date : | March 2008 |
| Actual Study Completion Date : | September 2009 |
-
Drug: raltegravir potassium
- OBT
- enfuvirtide
- Proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at week 24 [ Time Frame: week 24 ]
- Proportions of patients with HIV RNA levels of less than 50 copies/ml at week 48, with HIV RNA levels of less than 400 copies/ml at weeks 24 and 48 [ Time Frame: week 24 and 48 ]
- HIV RNA level evolution between baseline and week 48 [ Time Frame: from week 0 to 48 ]
- HIV proviral DNA and 2LTR circle HIV DNA between baseline and week 48 [ Time Frame: from week 0 to 48 ]
- Number and type of resistance mutations in case of virologic failure occurrence [ Time Frame: from week 0 to 48 ]
- CD4 lymphocyte count and proportion evolution between baseline and week 48 [ Time Frame: from week 0 to 48 ]
- HIV infection progression [ Time Frame: from week 0 to 48 ]
- Frequency of the study regimen modifications and interruption [ Time Frame: from week 0 to 48 ]
- Study regimen tolerance [ Time Frame: from week 0 to 48 ]
- Study regimen adherence [ Time Frame: from week 0 to 48 ]
- Association between study drugs' minimum concentrations at week 4 and week 12 and virologic success at week 24 [ Time Frame: from week 4 to 24 ]
- Evolution of pharmacokinetics parameters of study drugs in the PK substudy [ Time Frame: betwwen week 1 and 4 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age: 18 years and above
- Documented HIV-1 infection.
- History of virological failure on NNRTIs (patients with a history of toxicity to nevirapine and efavirenz may be enrolled in this study).
- On a combination antiretroviral therapy for at least 8 weeks prior to the screening visit (if on tipranavir, or enfuvirtide these drugs should have been introduced more than 8 weeks before the screening visit).
- Patient naive to darunavir, etravirine and to integrase inhibitors
- Plasma viral load at screening visit over 1000 copies/ml, (no CD4 restriction).
-
Genotypic resistance testing at the screening visit:
- Protease inhibitor mutations: over or equal to 3 primary protease inhibitor mutations among: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54M, L76V, V82A/F/L/T/S, I84V, N88S and L90M (IAS list 2006) but below or equal to 3 mutations among the following: V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V et L89V (virus sensitivity to darunavir/ritonavir).
- Reverse transcriptase mutations: over or equal to 3 NRTI mutations (among IAS list) and below or equal to 3 mutations among: A98G, L100I, K101Q/P/E, K103H/N/S/T, V106A/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V/C/H/L, Y188C/H/L, G190A/C/E/Q/S, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F (virus sensitivity to etravirine)
Exclusion Criteria:
- Non effective barrier contraception in women of child bearing potential
- Pregnant women or women who are breastfeeding
- Opportunistic infection at the acute phase
- Decompensated cirrhosis (stage B or C of Child-Pugh score)
- Malignancy requiring chemotherapy or radiotherapy
- Contraindicated medications being taken by the patient (listed in protocol)
- Allergy to the active substances and expedients of darunavir, etravirine and raltegravir.
- Haemoglobin < 7g/dl, neutrophil cell count < 500/mm3, platelets < 50,000/mm3, creatinine clearance < 50 ml/mn, P. alkaline, AST, ALT or total bilirubin over or equal to 3 times normal values.
- Patients receiving experimental agents with an exclusion period for participation in other studies applicable at the screening visit of the current study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00460382
| France | |
| Hôpital Gustave Dron, Service Maladies Infectieuses | |
| Tourcoing, France, 59208 | |
| Principal Investigator: | Yazdan YAZDANPANAH, MD PHD | Hôpital Tourcoing FRANCE | |
| Study Director: | Geneviève CHENE, MD PHD | INSERM U897 BORDEAUX FRANCE |
| Responsible Party: | French National Agency for Research on AIDS and Viral Hepatitis |
| ClinicalTrials.gov Identifier: | NCT00460382 History of Changes |
| Other Study ID Numbers: |
2007-000670-23 ANRS 139 TRIO |
| First Posted: | April 13, 2007 Key Record Dates |
| Last Update Posted: | September 17, 2010 |
| Last Verified: | September 2010 |
Keywords provided by French National Agency for Research on AIDS and Viral Hepatitis:
|
HIV infections HIV integrase inhibitor etravirine darunavir |
MK 0518 raltegravir Treatment Experienced Antiviral drug resistance |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Darunavir Raltegravir Potassium Enfuvirtide Etravirine HIV Protease Inhibitors |
Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors HIV Integrase Inhibitors Integrase Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors HIV Fusion Inhibitors Viral Fusion Protein Inhibitors |